Targeting HER2 beyond breast cancer.
Targeted therapies
cancer
immunotherapy
Journal
Molecular & cellular oncology
ISSN: 2372-3556
Titre abrégé: Mol Cell Oncol
Pays: United States
ID NLM: 101642411
Informations de publication
Date de publication:
2019
2019
Historique:
received:
21
12
2018
revised:
14
01
2019
accepted:
16
01
2019
entrez:
28
5
2019
pubmed:
28
5
2019
medline:
28
5
2019
Statut:
epublish
Résumé
The structural basis of blocking human epidermal growth factor receptor-2 (HER2) dimerization remains of great interest to generate effective anti-cancer therapies. Despite clinically feasible outcome in mammary tumors, a fine consensus between efficacy and safety remains a critical challenge beyond breast cancer. Here we extrapolate on the balancing act using recently reported clinical findings in salivary ductal carcinomas.
Identifiants
pubmed: 31131305
doi: 10.1080/23723556.2019.1571984
pii: 1571984
pmc: PMC6512921
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1571984Subventions
Organisme : NCI NIH HHS
ID : R01 CA233752
Pays : United States
Références
Br J Cancer. 2002 Jul 1;87(1):21-7
pubmed: 12085250
Lupus. 2010 Oct;19(12):1384-90
pubmed: 20947546
N Engl J Med. 2012 Jan 12;366(2):109-19
pubmed: 22149875
J Hematol Oncol. 2013 Jan 04;6:1
pubmed: 23286345
J Transl Med. 2013 Dec 12;11:307
pubmed: 24330813
J Biol Chem. 2017 Mar 3;292(9):3900-3908
pubmed: 28077575
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Cancer Cell. 2018 Aug 13;34(2):331-345.e11
pubmed: 30107179
J Clin Oncol. 2019 Jan 10;37(2):125-134
pubmed: 30452336
Oncotarget. 2018 Nov 2;9(86):35687-35704
pubmed: 30479698